news
Cancer immunotherapy drug discovery outsourcing size to increase globally
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
List view / Grid view
Immuno-oncology
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
news
Novel method could determine which lymphoma patients will respond to CAR T-cell therapy
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
news
Blocking trogocytosis improves ability of CAR T-cell therapy to treat cancer in mice
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
news
New immunotherapy method to find antigens that trigger specific T cells
The approach mimics the physical forces exerted by T cells as they crawl over host cells, could help scientists develop more effective cancer immunotherapies.
news
Cellular ‘waste product’ could enhance cancer immunotherapy, study shows
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
news
Findings on pancreatic cancer could improve immunotherapies
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
news
RASA2 gene make T cells more resilient
New study finds that using CRISPR to block RASA2 gene makes T cells more resilient against cancer.
news
Researchers find CD39 inhibition could be an effective strategy for immunotherapy
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
news
New method by which T cells can react to lower doses of antigens
Researchers have discovered a way to ignite T cells, potentially increasing the scope and success of T cell-based immunotherapy.
news
Combining immunotherapy and virotherapy shows promise for treatment-resistant cancers
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
news
A new strategy to overcome tumour-induced immunosuppression
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
news
Researchers halt the growth of multiple myeloma in mice
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
